Literature DB >> 9924843

A method of conducting therapeutic sessions with MDMA.

G R Greer1, R Tolbert.   

Abstract

A method for preparing clients and conducting therapeutic sessions with 3,4-methylenedioxymethamphetamine (MDMA) is described, with emphasis on the need for careful attention to the mental set of therapists and clients and the setting of the session. The therapists' belief was that MDMA inhibited the fear response to a perceived emotional threat, allowing the client to place the emotional sequelae of past experiences into a more realistic perspective in their current emotional lives and relationships. Clients were carefully screened and prepared until they had a clear purpose for the session, including a willingness to experience and to learn from anything that might happen. Sympathomimetic effects of MDMA determined the medical contraindications, and clients with histories of serious functional psychiatric impairments were excluded. Total doses of 75-150 mg, plus 50 mg if requested later, were administered, followed by clients lying down and listening to music with eyeshades and headphones during the peak MDMA effect. Screening and follow-up questionnaires were utilized. Two case histories are presented: a man achieving relief of pain from multiple myeloma, and a woman finding relief from problems as the daughter of Holocaust survivors. Use of consciousness-altering drugs in other contexts is discussed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9924843     DOI: 10.1080/02791072.1998.10399713

Source DB:  PubMed          Journal:  J Psychoactive Drugs        ISSN: 0279-1072


  21 in total

1.  "The Great Unmentionable": Exploring the Pleasures and Benefits of Ecstasy from the Perspectives of Drug Users.

Authors:  Geoffrey Hunt; Kristin Evans
Journal:  Drugs (Abingdon Engl)       Date:  2008

Review 2.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

Review 3.  Serotonin 2A receptors are a stress response system: implications for post-traumatic stress disorder.

Authors:  Kevin Sean Murnane
Journal:  Behav Pharmacol       Date:  2019-04       Impact factor: 2.293

Review 4.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

5.  Intimate insight: MDMA changes how people talk about significant others.

Authors:  Matthew J Baggott; Matthew G Kirkpatrick; Gillinder Bedi; Harriet de Wit
Journal:  J Psychopharmacol       Date:  2015-04-28       Impact factor: 4.153

Review 6.  The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review.

Authors:  A C Parrott
Journal:  Psychopharmacology (Berl)       Date:  2007-02-13       Impact factor: 4.530

Review 7.  Legal highs: staying on top of the flood of novel psychoactive substances.

Authors:  David Baumeister; Luis M Tojo; Derek K Tracy
Journal:  Ther Adv Psychopharmacol       Date:  2015-04

8.  Amphetamine analogs methamphetamine and 3,4-methylenedioxymethamphetamine (MDMA) differentially affect speech.

Authors:  Gina F Marrone; Jennifer S Pardo; Robert M Krauss; Carl L Hart
Journal:  Psychopharmacology (Berl)       Date:  2009-11-17       Impact factor: 4.530

Review 9.  Club drugs: review of the 'rave' with a note of concern for the Indian scenario.

Authors:  Kaustav Chakraborty; Rajarshi Neogi; Debasish Basu
Journal:  Indian J Med Res       Date:  2011-06       Impact factor: 2.375

10.  Effects of Schedule I drug laws on neuroscience research and treatment innovation.

Authors:  David J Nutt; Leslie A King; David E Nichols
Journal:  Nat Rev Neurosci       Date:  2013-06-12       Impact factor: 34.870

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.